Santhera Appoints Stifel as Financial Advisor
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy SF?
Source: Yahoo Finance
- Advisor Appointment: Santhera Pharmaceuticals has appointed Stifel Nicolaus Europe Limited as its new corporate finance advisor, focusing on capital markets and international institutional investors, thereby enhancing its influence in the capital markets.
- Partnership Continuation: Octavian AG will continue to act as the company's finance advisor, collaborating with Stifel to broaden the investor base and increase the company's visibility and attractiveness in the global market.
- Innovative Drug Development: Santhera focuses on developing innovative medicines for rare neuromuscular diseases, with AGAMREE® (vamorolone) approved in multiple countries, showcasing the company's potential in addressing high unmet medical needs.
- Global Market Strategy: AGAMREE® has received approvals in the U.S., EU, UK, and other regions, and has been out-licensed to Catalyst Pharmaceuticals, Sperogenix Therapeutics, and Nxera Pharma, indicating Santhera's strategic positioning and collaboration intentions in the global market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SF?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SF
Wall Street analysts forecast SF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SF is 143.67 USD with a low forecast of 133.00 USD and a high forecast of 155.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 130.610
Low
133.00
Averages
143.67
High
155.00
Current: 130.610
Low
133.00
Averages
143.67
High
155.00
About SF
Stifel Financial Corp. is a financial holding company. The Company's principal subsidiary is Stifel, Nicolaus & Company, Incorporated, a full-service retail and institutional wealth management and investment banking company. The Company’s segments include Global Wealth Management, Institutional Group, and Other. Its Global Wealth Management segment provides securities transaction, brokerage, and investment services to its clients through the consolidated Stifel branch system. The Institutional Group segment includes research, equity and fixed income institutional sales and trading, investment banking, public finance, and syndicate. The Other segment includes interest income from stock borrowing activities, unallocated interest expense, interest income and gains and losses from investments held, amortization of stock-based awards for certain administrative associates; and all unallocated overhead costs associated with the execution of orders; custody of client securities, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Santhera Appoints Stifel as Financial Advisor
- Advisor Appointment: Santhera Pharmaceuticals has appointed Stifel Nicolaus Europe Limited as its new corporate finance advisor, focusing on capital markets and international institutional investors, thereby enhancing its influence in the capital markets.
- Partnership Continuation: Octavian AG will continue to act as the company's finance advisor, collaborating with Stifel to broaden the investor base and increase the company's visibility and attractiveness in the global market.
- Innovative Drug Development: Santhera focuses on developing innovative medicines for rare neuromuscular diseases, with AGAMREE® (vamorolone) approved in multiple countries, showcasing the company's potential in addressing high unmet medical needs.
- Global Market Strategy: AGAMREE® has received approvals in the U.S., EU, UK, and other regions, and has been out-licensed to Catalyst Pharmaceuticals, Sperogenix Therapeutics, and Nxera Pharma, indicating Santhera's strategic positioning and collaboration intentions in the global market.
See More
2nd LA CorpGov Forum Set for September 18 Featuring Sports, Entertainment & M&A
- Event Date and Venue: The 2nd LA CorpGov Forum is scheduled for September 18, 2026, at 2:30 PM at The Huntington Library in San Marino, California, aiming to attract numerous institutional investors and corporate executives to foster industry networking and collaboration.
- Rich Agenda: The forum will feature multiple panels, fireside chats, and networking opportunities, with a reception at 5:00 PM offering cocktails and hors d’oeuvres, enhancing relationship-building among attendees.
- Digital Report Publication: The event will be filmed with multiple 4K cameras and professionally edited, resulting in a report that will be published by CorpGov and its content partners like Yahoo Finance and Bloomberg, ensuring broad dissemination and impact of the insights shared.
- First Forum Recap: The inaugural LA CorpGov Forum took place on September 4, 2025, in Los Angeles, attracting over 100 institutional investors and corporate executives to discuss critical topics such as IPOs and shareholder activism, underscoring the forum's significance and influence within the industry.
See More
Consumer Staples Appear Expensive: Explore Clorox and Other High-Yield Stocks with Strong Dividends.
- Market Shift: There is a significant rotation from software stocks to safer investments like consumer staples.
- Investor Sentiment: Investors are concerned that advancements in AI, such as ChatGPT, may negatively impact service-oriented businesses while benefiting manufacturers of household products.
See More
Braze Stock Price Target Cut Again, Analyst Sees Growth Potential
- Price Target Reduction: Stifel analyst Parker Lane cut Braze's price target from $45 to $40 while maintaining a buy rating, indicating recognition of the company's future growth opportunities.
- Investor Sentiment Decline: Braze's stock fell 0.7% in today's trading, recovering from an earlier decline of 5.2%, reflecting a cautious market attitude towards the tech stock.
- Improved Financial Performance: In Q3 2025, Braze reported a 25% year-over-year revenue increase with free cash flow of $17.8 million, a significant improvement compared to negative free cash flow of $14.2 million during the same period last year.
- Valuation Appeal: Braze shares are currently trading at 2.7 times sales, a discount to the five-year average price-to-sales ratio of 6.2, indicating attractive investment opportunities in the artificial intelligence sector.
See More
Stifel Analyst Lowers Braze Price Target to $40
- Price Target Cut: Stifel analyst Parker Lane has lowered the price target for Braze stock from $45 to $40 while maintaining a buy rating, indicating a decline in investor sentiment that has led to a drop in stock price despite the company's growth potential.
- Strong Financial Performance: In Q3 2025, Braze reported a 25% year-over-year revenue increase, achieving $17.8 million in free cash flow compared to a negative $14.2 million during the same period last year, highlighting significant financial improvement.
- Attractive Market Valuation: With shares trading at 2.7 times sales, a discount to the five-year average price-to-sales ratio of 6.2, Braze stock is positioned as an appealing option for investors looking for exposure to artificial intelligence.
- Investor Recommendations: Although Braze was not included in the Motley Fool Stock Advisor's top ten stock picks, analysts emphasize the company's strong fundamentals and growth opportunities, suggesting that investors focus on these aspects rather than solely on price targets.
See More
Microsoft Shares Drop Following Analyst Downgrade
- Stock Price Decline: Microsoft (MSFT) shares fell nearly 5% on Thursday, closing at $393.58 with a market cap of $3.1 trillion, reflecting heightened negative sentiment towards software stocks.
- Analyst Rating Change: Stifel's analyst Brad Reback downgraded Microsoft's rating from 'Buy' to 'Hold' and significantly reduced the price target from $540 to $392, indicating a bearish outlook on the company's future financial performance.
- Increased Capex Forecast: Reback raised his forecast for Microsoft's capital expenditures to $200 billion for fiscal 2027, well above the $160 billion average expected by analysts, which could pressure the company's profitability.
- Market Sentiment Impact: The sell-off of Microsoft is largely driven by panic and herd behavior, yet despite short-term challenges, the company maintains diverse revenue streams, suggesting a positive long-term growth outlook.
See More
Santhera Appoints Stifel as Financial Advisor
- Advisor Appointment: Santhera Pharmaceuticals has appointed Stifel Nicolaus Europe Limited as its new corporate finance advisor, focusing on capital markets and international institutional investors, thereby enhancing its influence in the capital markets.
- Partnership Continuation: Octavian AG will continue to act as the company's finance advisor, collaborating with Stifel to broaden the investor base and increase the company's visibility and attractiveness in the global market.
- Innovative Drug Development: Santhera focuses on developing innovative medicines for rare neuromuscular diseases, with AGAMREE® (vamorolone) approved in multiple countries, showcasing the company's potential in addressing high unmet medical needs.
- Global Market Strategy: AGAMREE® has received approvals in the U.S., EU, UK, and other regions, and has been out-licensed to Catalyst Pharmaceuticals, Sperogenix Therapeutics, and Nxera Pharma, indicating Santhera's strategic positioning and collaboration intentions in the global market.
See More
2nd LA CorpGov Forum Set for September 18 Featuring Sports, Entertainment & M&A
- Event Date and Venue: The 2nd LA CorpGov Forum is scheduled for September 18, 2026, at 2:30 PM at The Huntington Library in San Marino, California, aiming to attract numerous institutional investors and corporate executives to foster industry networking and collaboration.
- Rich Agenda: The forum will feature multiple panels, fireside chats, and networking opportunities, with a reception at 5:00 PM offering cocktails and hors d’oeuvres, enhancing relationship-building among attendees.
- Digital Report Publication: The event will be filmed with multiple 4K cameras and professionally edited, resulting in a report that will be published by CorpGov and its content partners like Yahoo Finance and Bloomberg, ensuring broad dissemination and impact of the insights shared.
- First Forum Recap: The inaugural LA CorpGov Forum took place on September 4, 2025, in Los Angeles, attracting over 100 institutional investors and corporate executives to discuss critical topics such as IPOs and shareholder activism, underscoring the forum's significance and influence within the industry.
See More
Consumer Staples Appear Expensive: Explore Clorox and Other High-Yield Stocks with Strong Dividends.
- Market Shift: There is a significant rotation from software stocks to safer investments like consumer staples.
- Investor Sentiment: Investors are concerned that advancements in AI, such as ChatGPT, may negatively impact service-oriented businesses while benefiting manufacturers of household products.
See More
Braze Stock Price Target Cut Again, Analyst Sees Growth Potential
- Price Target Reduction: Stifel analyst Parker Lane cut Braze's price target from $45 to $40 while maintaining a buy rating, indicating recognition of the company's future growth opportunities.
- Investor Sentiment Decline: Braze's stock fell 0.7% in today's trading, recovering from an earlier decline of 5.2%, reflecting a cautious market attitude towards the tech stock.
- Improved Financial Performance: In Q3 2025, Braze reported a 25% year-over-year revenue increase with free cash flow of $17.8 million, a significant improvement compared to negative free cash flow of $14.2 million during the same period last year.
- Valuation Appeal: Braze shares are currently trading at 2.7 times sales, a discount to the five-year average price-to-sales ratio of 6.2, indicating attractive investment opportunities in the artificial intelligence sector.
See More
Stifel Analyst Lowers Braze Price Target to $40
- Price Target Cut: Stifel analyst Parker Lane has lowered the price target for Braze stock from $45 to $40 while maintaining a buy rating, indicating a decline in investor sentiment that has led to a drop in stock price despite the company's growth potential.
- Strong Financial Performance: In Q3 2025, Braze reported a 25% year-over-year revenue increase, achieving $17.8 million in free cash flow compared to a negative $14.2 million during the same period last year, highlighting significant financial improvement.
- Attractive Market Valuation: With shares trading at 2.7 times sales, a discount to the five-year average price-to-sales ratio of 6.2, Braze stock is positioned as an appealing option for investors looking for exposure to artificial intelligence.
- Investor Recommendations: Although Braze was not included in the Motley Fool Stock Advisor's top ten stock picks, analysts emphasize the company's strong fundamentals and growth opportunities, suggesting that investors focus on these aspects rather than solely on price targets.
See More
Microsoft Shares Drop Following Analyst Downgrade
- Stock Price Decline: Microsoft (MSFT) shares fell nearly 5% on Thursday, closing at $393.58 with a market cap of $3.1 trillion, reflecting heightened negative sentiment towards software stocks.
- Analyst Rating Change: Stifel's analyst Brad Reback downgraded Microsoft's rating from 'Buy' to 'Hold' and significantly reduced the price target from $540 to $392, indicating a bearish outlook on the company's future financial performance.
- Increased Capex Forecast: Reback raised his forecast for Microsoft's capital expenditures to $200 billion for fiscal 2027, well above the $160 billion average expected by analysts, which could pressure the company's profitability.
- Market Sentiment Impact: The sell-off of Microsoft is largely driven by panic and herd behavior, yet despite short-term challenges, the company maintains diverse revenue streams, suggesting a positive long-term growth outlook.
See More
